675 studies (9 from unattributed sources) on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Bfflist Amo | 247 | 99.61% | View COA → |
| Sry Labs | 207 | 99.55% | View COA → |
| Shanghai Sigma Audley Ssa | 140 | 99.56% | View COA → |
| Hk Peptides | 133 | 99.76% | View COA → |
| Allen Biotechnology Co Abc | 124 | 99.66% | View COA → |
| Planet Peptide | 105 | 99.76% | View COA → |
| Zlz Peptide | 94 | 99.72% | View COA → |
| GYC | 93 | 99.73% | View COA → |
Recent certificates: #27962 (99.94%) · #28001 (99.52%) · #30760 (99.98%) · #31566 (99.96%) · #42192 (99.69%) · #42719 (99.95%)
Manufacturers with published third-party certificates of analysis for Tirzepatide. Open a vendor to see every batch we've verified.
This model-based analysis provides a crucial quantitative framework for **individualized treatment decisions** in **Type 2 Diabetes** and obesity, especially where direct head-to-head trials are unavailable. For clini…
Identifying this specific obesity subphenotype with reduced endogenous GLP-1 synthesis and enhanced **tirzepatide** response represents a significant step towards precision medicine in obesity management. **This findi…
This review highlights that **semaglutide** and **tirzepatide** may offer multiple benefits for adults with autoimmune diabetes who retain residual **beta-cell function**, particularly those with **LADA**. For clinici…
This case report suggests that **Tirzepatide, when used after psychotherapy, may be a safe and effective option for individuals with binge-eating disorder and obesity**, potentially leading to both ED remission and si…
**This case report suggests a powerful new strategy for tackling complex periprosthetic fracture nonunions, especially in medically fragile patients.** The integration of a biomimetic hematoma scaffold delivering **rh…
This pharmacovigilance study provides crucial insights into the real-world safety profile of tirzepatide, particularly concerning ketoacidosis-spectrum events. **Clinicians prescribing tirzepatide should counsel patie…
This commentary highlights a critical emerging safety signal for widely used GLP-1RA and GIP/GLP-1RA medications. **Clinicians must be aware of the possibility of hair loss occurring with GLP-1RAs** and proactively in…
Tirzepatide significantly reduced hepatic steatosis and inflammation in a mouse MASLD model, downregulating `CCL2/CCR2` and `PI3K-AKT` pathways.
This study provides compelling real-world evidence that **tirzepatide offers a potent non-surgical option for managing recurrent weight gain after bariatric procedures**. For individuals who have undergone BS or EBT b…
This extensive prospective cohort study is critical for understanding the real-world efficacy and safety of combining GLP-1 medications with structured digital health interventions. **The findings will inform optimal …
Self-administered **tirzepatide** led to starvation ketosis and subsequent anorexia nervosa diagnosis in a 21-year-old woman, highlighting risks of unsupervised use.
This study provides critical real-world evidence on the safety profile of GLP-1 based therapies, highlighting a statistically significant, albeit low absolute, increased risk of severe GI motility issues. **Clinicians…
**Attempting to microdose Tirzepatide using standard multi-dose pens is highly problematic and carries substantial risks due to dose inaccuracy and potential contamination.** This discussion clarifies that while the c…
This review underscores that **improving GLP-1RA adherence requires a holistic approach beyond simply managing side effects**. For peptide users and clinicians, it highlights the need to consider patient expectations,…
These real-world findings suggest that **tirzepatide** may offer significant benefits beyond its established roles in diabetes and obesity, potentially improving critical outcomes for patients with **COPD**. **For ind…
This case report suggests **tirzepatide may offer a promising therapeutic strategy for Smith-Magenis syndrome**, addressing both the challenging hyperphagia-driven obesity and severe behavioral dysregulation. This dua…
This preclinical finding suggests a novel therapeutic strategy for **opioid use disorder (OUD)**, particularly for fentanyl addiction. **Semaglutide**, already approved for diabetes and weight management, could be rep…
A prospective pilot study explores if GLP-1 RAs improve pain, disability, and quality of life in obese adults with chronic low back pain.
This annual compilation from the PEER team is invaluable for **primary care clinicians seeking to maintain evidence-based practice without being overwhelmed by the sheer volume of new research**. By curating and summa…
**Improving the reliability and accuracy of biomedical knowledge graphs** is paramount for accelerating critical processes in drug discovery, target identification, and the advancement of personalized medicine. By pre…
**Clinicians prescribing GLP-1 receptor agonists should be aware of a potential association with increased rates of upper eyelid blepharoplasty**, and consider discussing this with patients, particularly those with co…
Tirzepatide shows promise for managing **obesity** and maladaptive behaviors in a **31-year-old female** with **Smith-Magenis syndrome**, highlighting its potential beyond typical applications.
For individuals with **Type 1 Diabetes (T1DM)**, **tirzepatide** could represent a significant adjunctive therapy, offering improved glycemic control and substantial reductions in daily insulin dosage. **This could le…
This real-world data suggests that **tirzepatide** can be a valuable component of a comprehensive metabolic management strategy for patients with **psoriasis** and **obesity**. The observed improvements in weight, glu…
A Phase 2 trial will evaluate **tirzepatide** in Wolfram Syndrome Type 1 patients to increase endogenous insulin and correct glycemic lability.
These findings suggest that GLP-1 RAs offer a promising non-surgical therapeutic avenue for individuals suffering from **chronic low back pain** compounded by **obesity**. The dual benefit of significant weight loss a…
This real-world data from an Indian cohort provides crucial insights for **personalizing GLP-1/GIP agonist therapy** and managing patient expectations. The finding that **tirzepatide** leads to greater weight loss tha…
Tirzepatide reduced 1-year venous thromboembolism risk by **10%** (HR **0.90**, p=**0.011**) and pulmonary embolism by **12%** (HR **0.88**, p=**0.021**) compared to GLP-1 RAs in **701,374** obese patients.
**Clinicians should proactively screen GLP-1RA patients for pre-existing constipation** before initiating treatment. This finding suggests that managing constipation in GLP-1RA users might often involve addressing a c…
This study suggests a potent new strategy for managing **PCOS** in overweight/obese women, particularly those struggling with weight loss and fertility. **Combining low-dose tirzepatide with metformin offers superior …
For individuals managing **type 2 diabetes** and **ASCVD**, **tirzepatide** now stands as a robust option for cardiovascular risk reduction, demonstrating comparable efficacy to the established **GLP-1RA dulaglutide**…
**This analysis underscores the potential for GLP-1/GIP co-agonists to offer superior cardio-metabolic protection compared to GLP-1 monotherapy, shifting the paradigm for managing type 2 diabetes and obesity.** For cl…
This study provides compelling evidence that **tirzepatide offers comprehensive cardiovascular risk reduction beyond its established benefits in weight loss and glycemic control**. The significant, dose-dependent impr…
Adolescents and young adults (AYAs) and their caregivers face complex decisions regarding weight loss medications, experiencing reduced appetite and improved well-being, alongside stigma.
This direct comparative trial is crucial for optimizing **incretin-based pharmacotherapy** for obesity and metabolic syndrome. By meticulously quantifying differences in adipose remodeling, liver fat reduction, and ov…
If successful, this trial could establish **tirzepatide** as a novel, dual-action therapeutic for **smoking cessation**, particularly beneficial for people who smoke with **overweight or obesity**. This could offer a …
This study provides crucial real-world evidence for clinicians, especially anesthesiologists, to optimize perioperative patient management. **Early recognition of drug-related IGE** is now better supported, allowing f…
Achieving a lower BMI category with **tirzepatide** translates into clinically meaningful improvements in a wide array of cardiometabolic risk factors, reinforcing its potential to profoundly impact **obesity** manage…
Understanding the precise molecular mechanisms of **GLP-1R agonists** and dual **GIPR/GLP-1R agonists** in human adipocytes is crucial for optimizing their therapeutic potential beyond weight loss. **Future research s…
This study provides compelling real-world evidence that **GLP-1 RAs may offer a disease-modifying benefit for knee osteoarthritis**, extending beyond mere pain reduction to potentially delay or prevent the need for to…
This case report highlights a critical safety concern for clinicians prescribing **tirzepatide** or other GLP-1/GIP receptor agonists to patients on lithium therapy. **Close monitoring of lithium plasma levels is esse…
This large-scale pharmacovigilance study provides reassuring real-world safety data for GLP-1 RAs, suggesting they do not carry a disproportionate risk of thrombotic events. **This finding reinforces the favorable saf…
This research significantly expands our understanding of tirzepatide's mechanism of action, revealing its ability to activate brown adipose tissue and boost energy expenditure, beyond its known effects on appetite and…
A study will evaluate Bimagrumab and Tirzepatide, alone or combined, for efficacy and safety in adults with obesity or overweight without Type 2 Diabetes.
This case report highlights a previously undescribed adverse event profile for **tirzepatide**, particularly when combined with calcium supplementation. **Clinicians must closely monitor patients' electrolytes, especi…
This review underscores a significant paradigm shift, suggesting that **GLP-1RAs**, commonly used for diabetes and obesity, could offer a novel therapeutic avenue for chronic inflammatory skin diseases. For peptide us…
This study provides compelling evidence that adjuvant **semaglutide** and **tirzepatide** can significantly improve long-term weight loss maintenance after **sleeve gastrectomy**, even when started many years post-ope…
Tirzepatide combined with LNG-IUD is being studied in a Phase II trial to improve pathologic response in overweight/obese women with atypical endometrial hyperplasia or grade 1 endometrial cancer.
Study to assess if weight loss, potentially with **GLP-1 receptor agonists**, improves **plaque psoriasis** treatment efficacy in overweight/obese Chinese patients.
**This study highlights a critical safety concern for individuals using tirzepatide who require anesthesia.** If the hypothesis is confirmed, current pre-anesthetic fasting guidelines may be insufficient for **tirzepa…
Free, no account — handy when you're working with Tirzepatide.